公开(公告)号：US20230183286A1

公开(公告)日：2023-06-15

申请号：US17820005

申请日：2022-08-16

申请人： NOVARTIS AG

发明人： David BARNES-SEEMAN ,  Scott Louis COHEN ,  John Louis DIENER ,  Christian GAMPE ,  James ROACHE ,  Amy White ,  Sarah Louise Williams ,  Jun Yuan ,  Frederic Zecri

IPC分类号： C07H21/02 ,  C07F9/6561 ,  C07H19/167 ,  C07H19/207 ,  C07K14/575

CPC分类号： C07H21/02 ,  C07F9/65616 ,  C07H19/167 ,  C07H19/207 ,  C07K14/5759

摘要： The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.

公开(公告)号：US11672782B2

公开(公告)日：2023-06-13

申请号：US17089064

申请日：2020-11-04

申请人： Novartis AG

发明人： Kamlesh Jagdis Bala ,  Andrew Brearley ,  James Dale ,  Anne-Marie Edwards ,  Mahbub Ahmed ,  David Porter ,  Robert Alexander Pulz ,  Lisa Ann Rooney ,  David Andrew Sandham ,  Duncan Shaw ,  Nichola Smith ,  Jessica Louise Taylor ,  Roger John Taylor ,  Thomas Josef Troxler ,  Joe Wrigglesworth

IPC分类号： A61K31/422 ,  A61K31/4155 ,  C07D413/12 ,  C07D413/14

CPC分类号： A61K31/422 ,  A61K31/4155 ,  C07D413/12 ,  C07D413/14 ,  A61K31/422 ,  A61K2300/00

摘要： The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;




a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20230149629A1

公开(公告)日：2023-05-18

申请号：US18097910

申请日：2023-01-17

申请人： Novartis AG

发明人： Nicholas Lee HAWSON ,  Martin MURPHY ,  Frederick William HAMLIN ,  Christophe ROYER ,  Dominic LLOYD-LUCAS ,  Tony BEDFORD ,  Andrew GOW ,  Dave HARRIS ,  Duncan Aleck BISHOP ,  Matthew GARWOOD ,  Matthew MURCHIE ,  Lasse MOGENSEN

IPC分类号： A61M5/178 ,  A61M5/24

CPC分类号： A61M5/1782 ,  A61M5/24 ,  A61M5/20

摘要： An injection device (10) comprises an injection solution receptacle (30) and a plunger (70) at feast a portion of which is slidably received in the injection solution receptacle (30), wherein the plunger (70) is displaceable relative to the injection solution receptacle (30) in a distal direction in order to expel an injection solution contained in the injection solution receptacle (30) from the injection solution receptacle (30). A first plunger stop mechanism (140) is adapted to stop a displacement of the plunger (70) relative to the injection solution receptacle (30) in the distal direction at a first dosing position (P1). A second plunger stop mechanism (140) is adapted to stop a displacement of the plunger (70) relative to the injection solution receptacle (30) from the first: dosing position (P1) in the distal direction at a second dosing position (P2), wherein the first and the second dosing position (P2) of the plunger (70) are selected in such a manner that the plunger (70), upon being displaced relative to the injection solution receptacle (30) between the first and the second dosing position (P2) is adapted to expel a desired dose of the injection solution contained in the injection solution receptacle (30) from the injection solution receptacle (30).

公开(公告)号：US11642315B2

公开(公告)日：2023-05-09

申请号：US16652097

申请日：2018-09-28

申请人： NOVARTIS AG

发明人： Elodia Di Renzo ,  David Hook ,  Markus Krumme ,  Steffen Lang ,  Massimo Moratto ,  Joerg Ogorka ,  Jim Parks ,  Dale Ploeger ,  Norbert Rasenack ,  Hendrik Schneider ,  Stefan Steigmiller ,  Gordon Stout ,  Patrick Tritschler ,  Fabian Weber

IPC分类号： A61K9/48 ,  A61J3/07 ,  A61K9/00

CPC分类号： A61K9/4833 ,  A61J3/074 ,  A61K9/0053

摘要： A method of preparing a pharmaceutical product comprises the steps of (a) providing a neat active pharmaceutical ingredient (API) complying with at least five of the following parameters determined by using a FT4 powder rheometer: (i) specific basic flow energy of at most 60 mJ/g; (ii) stability index of 0.75 to 1.25; (iii) specific energy of at most 10 mJ/g; (iv) major principle stress at 15 kPa of at most 40; (v) flow function at 15 kPa of at least 1.3; (vi) consolidated bulk density at 15 kPa of at least 0.26 g/mL; (vii) compressibility of at most 47%; and (viii) wall friction angle of at most 40°; (b) dispensing the neat API of step (a) into a bottom part of a pharmaceutical carrier using a vacuum assisted metering and filling device; and (c) encapsulating the bottom part, thereby producing a pharmaceutical product.

公开(公告)号：US20230111593A1

公开(公告)日：2023-04-13

申请号：US17799171

申请日：2021-02-12

申请人： NOVARTIS AG ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Stephen SCHUSTER ,  Yubing TONG ,  Jayaram K. UDUPA ,  Drew A. TORIGIAN

IPC分类号： G16H50/50 ,  A61K35/17 ,  A61K38/17 ,  A61P35/00 ,  G06V10/82 ,  G06V10/764 ,  G06T7/00

摘要： This disclosure provides methods and systems for determining a lesion-level treatment response to a chimeric antigen receptor (CAR) therapy, e.g., a CAR CD19 therapy, and uses of said methods and systems for evaluating the responsiveness of a subject to a CAR CD19 therapy, and for treating a subject with a CAR CD19 therapy.

公开(公告)号：US20230090389A1

公开(公告)日：2023-03-23

申请号：US17905032

申请日：2021-02-26

申请人： Novartis AG

发明人： Diana GRAUS PORTA

IPC分类号： A61K31/506 ,  A61K31/497 ,  A61K31/4965

摘要： The present invention relates to a pharmaceutical combination comprising dabrafenib, an Erk-inhibitor and a SHP2 inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which MAPK pathway inhibition is beneficial, for example, in the treatment of cancers.

公开(公告)号：US20230089503A1

公开(公告)日：2023-03-23

申请号：US17858701

申请日：2022-07-06

申请人： NOVARTIS AG

发明人： Stephanie Kay DODD ,  Arnaud GRANDEURY ,  Emmanuel SUFFERT ,  Evgenia ROUSAKI

IPC分类号： C07D401/14

摘要： The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.

公开(公告)号：US11607486B2

公开(公告)日：2023-03-21

申请号：US16494231

申请日：2018-02-01

申请人： Novartis AG

发明人： Alain Schmidlin ,  Mario Iobbi ,  Erich Studer ,  Andrew Bryant ,  Chinmay Deodhar ,  Rajan Patel

IPC分类号： A61M5/142 ,  A61M5/145 ,  A61M5/158

摘要： The invention concerns an injector device (100), comprising access means (110, 115) configured to selectively allow and prevent a cartridge (120) storing a pharmaceutical product (122) from being removed from the injector device (100), a self-test unit (130) configured to cause a self-test of at least one of an electronic component and an electronic assembly of the injector device (100), and a control unit (140) configured to control the access means (110, 115) to allow the cartridge (120) to be removed from the injector device (100) in case the self-test has failed.

公开(公告)号：US20230085472A1

公开(公告)日：2023-03-16

申请号：US17645071

申请日：2021-12-20

申请人： Novartis AG

发明人： David CARCACHE ,  Florian GRUBER ,  Danilo GUERINI ,  Martin GUNZENHAUSER ,  Richard HENG ,  Francesca PERRUCCIO ,  Oliver SIMIC ,  Carsten SPANKA

IPC分类号： C07D401/14 ,  A61K45/06 ,  A61K31/4196 ,  A61K31/5377 ,  A61K31/454

摘要： The present disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1 through R8 are as defined herein, and methods of making and using the same.

公开(公告)号：US20230052782A1

公开(公告)日：2023-02-16

申请号：US17784373

申请日：2020-12-11

申请人： Novartis AG

发明人： Frederick William HAMLIN ,  Anthony Jonathan BEDFORD ,  Duncan Aleck BISHOP ,  Andrew Murray GOW ,  David Stuart HARRIS ,  Nicholas Lee HAWSON ,  Jean-Paul KLEEVEN ,  Dominic LLOYD-LUCAS ,  David MUCIENTES ,  Martin Joseph MURPHY ,  Stephen PABOOJIAN

IPC分类号： A61M5/315 ,  A61M5/31

摘要： The present disclosure relates to an injection device, in particular a micro dose injection device such as, for example, an ophthalmic injection device. An example device comprises a rotatable plunger; a solution receptacle having a first end configured to slidably receive the rotatable plunger and a second end configured to dispense solution contained in the solution receptacle; a first stop member configured to prevent the rotatable plunger from being slidably displaced to a second position while the rotatable plunger is at a first position and in a first orientation; and a second stop member configured to prevent the rotatable plunger from rotating in a first direction about the first axis while the rotatable plunger is at the first position and in the first orientation, wherein slidably displacing the rotatable plunger from the first position to the second position dispenses a quantity of the solution contained in the solution receptacle.